News & Events about Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price objective upped by SVB Leerink from $32.00 to $33.00 in a research note issued to investors on Monday, Benzinga reports. SVB Leerink currently has a market perform rating on the stock. SVB Leerink also issued estimates for Ionis ...
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price objective upped by SVB Leerink from $32.00 to $33.00 in a research note issued to investors on Monday, Benzinga reports. SVB Leerink currently has a market perform rating on the stock. SVB Leerink also issued estimates for Ionis ...
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research PR...
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price target boosted by Piper Sandler from $60.00 to $62.00 in a report published on Thursday, The Fly reports. They currently have an overweight rating on the stock. Other analysts also recently issued reports about the stock. SVB Leerink ...
Latest Ratings for IONS
DateFirmActionFromTo Mar 2022GuggenheimInitiates Coverage OnBuy Mar 2022CitigroupInitiates Coverage OnSell Feb 2022SVB LeerinkMaintainsMarket Perform
View More Analyst Ratings for IONS
View the Latest Analyst Ratings
read more...